Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar + IP in 2nd-line Advanced Esophageal Squamous Cell Carcinoma
NCT03797625Phase 2Completed
- Sponsor
- Fudan University
- Start
- May 2017
- Primary completion
- Dec 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fudan University. Primary endpoint: Progression Free Survival. Started May 2017; status: completed.
02
Drugs
endostar
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03797625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797625.